GlassScriptPhysician profile
Thomas Alan Vo
NPI 1891289187
$2,126.97
in general payments reported to CMS, 2019-2025
18 companies · $961 in 2025
The $961 reported for 2025 was more than what a typical Cornea and External Diseases Specialist provider received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $123 · 2023: $164 · 2024: $879 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,004.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $431.13 | 2024-2025 | Rocklatan, Clareon, Rhopressa |
| Abbvie INC. | $244.50 | 2024-2025 | |
| Oyster Point Pharma, INC. | $227.42 | 2023-2025 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $161.26 | 2023-2024 | Cequa |
| Amgen INC. | $152.52 | 2024 | Tepezza |
| Astellas Pharma US INC | $125.00 | 2024 | Izervay |
| Carl Zeiss Meditec, INC. | $122.94 | 2022 | |
| Nova Eye, INC. | $98.29 | 2024-2025 | |
| Dompe US, INC. | $97.19 | 2025 | Oxervate |
| Bausch & Lomb Americas INC. | $96.99 | 2023-2024 | Xiidra, Miebo, Vyzulta |
| Sight Sciences, INC. | $71.87 | 2024-2025 | Omni Surgical System |
| Tarsus Pharmaceuticals, INC. | $65.57 | 2025 | Xdemvy |
| Harrow Eye, LLC | $57.94 | 2024 | Vevye |
| Rxsight INC | $49.60 | 2025 | Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Thea Pharma INC. | $47.32 | 2023-2024 | Iyuzeh |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $31.46 | 2024 | |
| Rayner Intraocular Lenses Limited | $28.53 | 2025 | Omidria |
| Horizon Therapeutics Plc | $17.44 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Vo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.